Stay updated on Stereotactic RT+Pembrolizumab in Oligometastatic Renal Cancer Clinical Trial
Sign up to get notified when there's something new on the Stereotactic RT+Pembrolizumab in Oligometastatic Renal Cancer Clinical Trial page.

Latest updates to the Stereotactic RT+Pembrolizumab in Oligometastatic Renal Cancer Clinical Trial page
- Check6 days agoNo Change Detected
- Check13 days agoChange DetectedThe page footer’s site revision indicator was updated from “Revision: v3.5.2” to “Revision: v3.5.3,” reflecting a platform/release change rather than any change to the trial information.SummaryDifference0.1%

- Check20 days agoChange DetectedRevision updated from v3.5.0 to v3.5.2.SummaryDifference0.1%

- Check27 days agoNo Change Detected
- Check49 days agoChange DetectedRevision: v3.5.0 was added and Revision: v3.4.3 was removed.SummaryDifference0.1%

- Check56 days agoChange DetectedRevision updated from v3.4.2 to v3.4.3.SummaryDifference0.1%

- Check71 days agoChange DetectedNo additions or deletions were detected on the page.SummaryDifference0.1%

- Check85 days agoChange DetectedAdded Revision: v3.4.2. Removed older notices about government funding lapse and NIH Clinical Center operating status; users are directed to opm.gov for current status updates.SummaryDifference0.4%

Stay in the know with updates to Stereotactic RT+Pembrolizumab in Oligometastatic Renal Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Stereotactic RT+Pembrolizumab in Oligometastatic Renal Cancer Clinical Trial page.